Keyphrases
Botswana
100%
Human Immunodeficiency Virus Type 1 (HIV-1)
73%
Antiretroviral Therapy
49%
AIDS/HIV
33%
Combined Antiretroviral Therapy (cART)
22%
HIV Patients
18%
HIV-1 Subtype C
16%
Highly Active Antiretroviral Therapy (HAART)
16%
Human Immunodeficiency Virus Type 2
15%
Efavirenz
14%
People Living with HIV (PLHIV)
14%
HIV Infection
13%
HIV-2
13%
Confidence Interval
12%
Disease Progression
12%
Virus
11%
Risk Factors
11%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
11%
Treatment Programs
11%
Antiretroviral Naïve
10%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
10%
Dakar
10%
Nevirapine
9%
CD4 Count
9%
Vaccine Design
9%
Antiviral Drugs
9%
Loss-to-follow-up
8%
Recombinant
8%
Senegal
8%
CD4+
7%
United States
7%
CD4+ T
7%
HIV RNA
7%
Lactic Acidosis
7%
HIV-positive
7%
Reverse Transcriptase
7%
HIV-1C
7%
Viral Load
6%
West Africa
6%
Sub-Saharan Africa
6%
Southern Africa
6%
Infected Patients
6%
Prostitutes
6%
Lymphocyte Count
6%
Clinical Trials
6%
Nave
5%
Virus Type
5%
Africa
5%
West African
5%
Zambia
5%
Immunology and Microbiology
Human Immunodeficiency Virus
92%
Human Immunodeficiency Virus 1
61%
Human Immunodeficiency Virus Type 1 Subtype C
23%
Human Immunodeficiency Virus 2
18%
Hepatitis B Virus
18%
CD4 Lymphocyte Count
17%
Monospecific Antibody
16%
Prevalence
15%
Viral Load
13%
CD4
13%
Human Immunodeficiency Virus Infection
12%
Reverse Transcriptase
11%
Hepatitis B
11%
T Cell
11%
Blood Plasma
10%
HIV Vaccine
9%
Human T-Lymphotropic Virus 1
8%
Western Blot
6%
Drug Resistance
5%
HIV Type 1
5%
Cytotoxic T Cell
5%
Acquired Immune Deficiency Syndrome
5%
Medicine and Dentistry
Human Immunodeficiency Virus
52%
Antiretroviral Therapy
37%
Cell Count
12%
Highly Active Antiretroviral Therapy
12%
Infection
10%
Clinical Trial
8%
Hepatitis B Virus
7%
Efavirenz
7%
Human Immunodeficiency Virus 1
6%
Pediatrics
6%
Breast Cancer
5%
Human Immunodeficiency Virus 2
5%
Lactic Acidosis
5%
Nevirapine
5%
